Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.

Biotechnology

Zai Lab

Samantha Du

Clark Gu

Philip Li

Andrew Zhu

Christine Chiou

Robert J. Brown

Yajing Chen

Rafael G. Amado

Peter Huang

Jonathan Wang

F. Ty Edmondson

James Yan

Josh Smiley

Ning Xu

R&D and Scientific Research Team

Clinical Operations Team

Leadership Team

Medical Affairs and Clinical Development

Finance and Procurement

Business Development and Strategy

Legal and Compliance Team

Teams at Zai Lab